Our portfolio

Synthetic biology application for living therapeutics design

Synlogic, a startup based in Boston, is developing a first-in-class synthetic biology platform for genetically engineering bacteria of the microbiome for delivery of therapeutics to the gut. Synlogic is initially focused on metabolic imbalance and inflammatory disease.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series A
  • Partnered in
    2014
  • Headquarters
    USA
  • Program strategy
    Enteric & Diarrheal Diseases

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.